BRPI0413255A - uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer - Google Patents

uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer

Info

Publication number
BRPI0413255A
BRPI0413255A BRPI0413255-6A BRPI0413255A BRPI0413255A BR PI0413255 A BRPI0413255 A BR PI0413255A BR PI0413255 A BRPI0413255 A BR PI0413255A BR PI0413255 A BRPI0413255 A BR PI0413255A
Authority
BR
Brazil
Prior art keywords
kinase inhibitor
inhibition
combination
growth factor
factor receptor
Prior art date
Application number
BRPI0413255-6A
Other languages
English (en)
Inventor
Lee Martin Greenberger
Carolyn Mary Discafani-Marro
Philip Frost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0413255A publication Critical patent/BRPI0413255A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE UMA COMBINAçãO DE UM INIBIDOR DE QUINASE DO RECEPTOR DO FATOR DE CRESCIMENTO EPIDéRMICO E AGENTES CITOTóXICOS PARA TRATAMENTO E INIBIçãO DO CáNCER". Essa invenção descreve combinações compreendendo um agente citotóxico e um inibidor de quinase EGFR, e métodos de tratar ou inibir câncer em um mamífero que necessite disso que compreende administrar a dito mamífero uma quantidade eficaz de um agente citotóxico e um inibidor de quinase EGFR.
BRPI0413255-6A 2003-08-01 2004-07-28 uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer BRPI0413255A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49213203P 2003-08-01 2003-08-01
PCT/US2004/024478 WO2005018677A2 (en) 2003-08-01 2004-07-28 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer

Publications (1)

Publication Number Publication Date
BRPI0413255A true BRPI0413255A (pt) 2006-10-03

Family

ID=34215843

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413255-6A BRPI0413255A (pt) 2003-08-01 2004-07-28 uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer

Country Status (19)

Country Link
US (1) US20050026933A1 (pt)
EP (1) EP1648516A2 (pt)
JP (1) JP2007501238A (pt)
KR (1) KR20060054412A (pt)
CN (1) CN1832757A (pt)
AR (1) AR045179A1 (pt)
AU (1) AU2004266572A1 (pt)
BR (1) BRPI0413255A (pt)
CA (1) CA2533126A1 (pt)
CO (1) CO5640151A2 (pt)
CR (1) CR8181A (pt)
EC (1) ECSP066341A (pt)
IL (1) IL173081A0 (pt)
MX (1) MXPA06001110A (pt)
NO (1) NO20060398L (pt)
RU (1) RU2006106267A (pt)
TW (1) TW200515910A (pt)
WO (1) WO2005018677A2 (pt)
ZA (1) ZA200600915B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622621B2 (en) * 2002-03-29 2009-11-24 Exxonmobil Chemical Patents Inc. Preparation of alkylaromatic hydrocarbons and alkylaryl sulfonates
RU2004131684A (ru) * 2002-03-29 2005-10-20 Эксонмобил Кемикэл Пейтенс Инк. (Us) Олигомеризация олефинов
ES2741574T3 (es) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
AU2005249200A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with oxaliplatin and an EGFR-inhibitor
NZ551431A (en) 2004-06-03 2010-04-30 Hoffmann La Roche Treatment with cisplatin and an EGFR-inhibitor
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP2594631A1 (en) 2005-04-05 2013-05-22 Cellpoint Diagnostics Devices and method for detecting circulating tumor cells and other particles
EP1871371A2 (en) * 2005-04-14 2008-01-02 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
US20080292729A1 (en) * 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
AR057854A1 (es) 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030891A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CN101522609A (zh) * 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
US20100111941A1 (en) * 2006-09-13 2010-05-06 Steven Deitcher Methods for treating cancer
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
WO2010028236A1 (en) * 2008-09-05 2010-03-11 Avila Therapeutics, Inc. Algorithm for designing irreversible inhibitors
RU2011139363A (ru) 2009-04-06 2013-05-20 ВАЙЕТ ЭлЭлСи Схема лечения рака молочной железы с использованием нератиниба
KR20120093220A (ko) * 2009-09-16 2012-08-22 아빌라 테라퓨틱스, 인크. 단백질 키나아제 컨쥬게이트 및 인히비터
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
UA77469C2 (en) * 2001-11-27 2006-12-15 White Holdings Corp 3-cyanoquinolines as egf-r and her2 kinase inhibitors

Also Published As

Publication number Publication date
CN1832757A (zh) 2006-09-13
TW200515910A (en) 2005-05-16
US20050026933A1 (en) 2005-02-03
NO20060398L (no) 2006-02-28
ECSP066341A (es) 2006-08-30
CR8181A (es) 2006-07-14
MXPA06001110A (es) 2006-04-11
AR045179A1 (es) 2005-10-19
EP1648516A2 (en) 2006-04-26
IL173081A0 (en) 2006-06-11
JP2007501238A (ja) 2007-01-25
RU2006106267A (ru) 2006-07-27
AU2004266572A1 (en) 2005-03-03
KR20060054412A (ko) 2006-05-22
CO5640151A2 (es) 2006-05-31
ZA200600915B (en) 2007-12-27
WO2005018677A2 (en) 2005-03-03
WO2005018677A3 (en) 2006-05-26
CA2533126A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0017075A (pt) Derivados de piridopirimidinona para tratamento de doença neurodegenerativa
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
NI200800060A (es) Bencimidazoles sustituidos como inhibidores de cinasa.
PA8537501A1 (es) Naftostirilos
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
ATE424208T1 (de) Proteinkinaseinhibitoren
BRPI0411239A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer inibição de canal de potássio, e, uso de um composto
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
BRPI0409473A (pt) combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 45/06 (2006.01), A61P 35/00 (2006.01), A61K 3